Ilke is a Research Specialist and applies her background as translational research scientist to support the Asset Selection analysts in collating medical data. Before RTW, she developed targeted gene therapies against hepatitis B virus and in genome-based technologies for discovery of novel anti-tuberculosis chemotherapies.
Ilke received her PhD in Biochemistry and Biotechnology jointly from Ghent University in Belgium and the University of Pretoria in South Africa. She joined RTW directly from academia and has major interest in delineating the role of genetics in human disease.
Nothing is more rewarding than contributing to a phenomenal vision for transforming healthcare by combining innovative technology with rare diseases and genetics. Ongoing medical advances in therapeutic development for rare disorders hold immense promise for patients. It is humbling and inspiring to be surrounded by a dynamic team of intelligent people committed to the evolution of medicine.